PGHL — Procter & Gamble Health Share Price
- IN₹78.60bn
- IN₹74.42bn
- IN₹12.30bn
- 96
- 18
- 65
- 67
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 9.75 | ||
Price to Tang. Book | 9.76 | ||
Price to Free Cashflow | 51.47 | ||
Price to Sales | 6.35 | ||
EV to EBITDA | 23.6 |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | 34.2% | ||
Return on Equity | 29.43% | ||
Operating Margin | 23.41% |
Financial Summary
Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 8,489.9 | 13,558.6 | 10,087.3 | 11,144.1 | 12,296.2 | 13,668 | n/a | 11.56% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +58.38 | +164.28 | -30.78 | +11.23 | +20.38 | +23.62 | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
Procter & Gamble Health Limited is an India-based company that is primarily engaged in the manufacturing of pharmaceutical products. The Company is engaged in the manufacturing and marketing of over-the-counter products, vitamins, minerals, and supplements products for a healthy lifestyle. The Company’s brands include Cosome, Evion, Neurobion, Seven Seas, Nasivion, Polybion, and Livogen. Cosome is a medicine which is used to help relieve dry coughs and related congestion symptoms. Evion is a Vitamin E capsules. The Evion range has different variants with different levels of Vitamin E, such as Evion 400, Evion 200, and Evion 600. Neurobion offers a range of neurotropic B-Vitamins which are a combination to help treat nerve damage and regenerate the nerves to relieve symptoms. Nasivion Classic Nasal Spray starts working on a blocked nose in 25 seconds. Polybion is a brand that helps with release and hence supports an active life.
Directors
- Suresh Talwar NEC (83)
- Amit Gupta CFO
- Zeal Shah CCO
- Vikas Gupta GCN
- Milind Thatte MDR
- Anand Nambiar DRC (43)
- Aalok Agrawal NED
- Hon Keong Choo NED
- Elizabeth Desmond NED
- Bradley Simpson NED
- Zoe Tang NED
- Rani Jadhav IND (66)
- H. C. H. Bhabha NID (59)
- C. R. Dua NID
- Subramanian Madhavan NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- April 26th, 1967
- Public Since
- November 21st, 1993
- No. of Shareholders
- 58,748
- No. of Employees
- 1,407
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 16,599,382
- Address
- Godrej One,, MUMBAI, 400079
- Web
- https://www.pghealthindia.com/
- Phone
- +91 2262109000
- Auditors
- Haribhakti & Co. LLP
Upcoming Events for PGHL
Q4 2024 Procter & Gamble Health Ltd Earnings Release
Similar to PGHL
Aarey Drugs and Pharmaceuticals
National Stock Exchange of India
Aarti Drugs
National Stock Exchange of India
Aarti Pharmalabs
National Stock Exchange of India
Abbott India
National Stock Exchange of India
Accent Microcell
National Stock Exchange of India
FAQ
As of Today at 19:17 UTC, shares in Procter & Gamble Health are trading at IN₹4,735.05. This share price information is delayed by 15 minutes.
Shares in Procter & Gamble Health last closed at IN₹4,735.05 and the price had moved by +4.87% over the past 365 days. In terms of relative price strength the Procter & Gamble Health share price has underperformed the S&P BSE 100 Index by -19.44% over the past year.
The overall consensus recommendation for Procter & Gamble Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Procter & Gamble Health dividend yield is 2.11% based on the trailing twelve month period.
Last year, Procter & Gamble Health paid a total dividend of IN₹100.00, and it currently has a trailing dividend yield of 2.11%. We do not have any data on when Procter & Gamble Health is to next pay dividends.
We do not have data on when Procter & Gamble Health is to next pay dividends. The historic dividend yield on Procter & Gamble Health shares is currently 2.11%.
To buy shares in Procter & Gamble Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹4,735.05, shares in Procter & Gamble Health had a market capitalisation of IN₹78.60bn.
Here are the trading details for Procter & Gamble Health:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: PGHL
Based on an overall assessment of its quality, value and momentum Procter & Gamble Health is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Procter & Gamble Health. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -20.46%.
As of the last closing price of IN₹4,735.05, shares in Procter & Gamble Health were trading -4.65% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Procter & Gamble Health PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at IN₹4,735.05.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Procter & Gamble Health's management team is headed by:
- Suresh Talwar - NEC
- Amit Gupta - CFO
- Zeal Shah - CCO
- Vikas Gupta - GCN
- Milind Thatte - MDR
- Anand Nambiar - DRC
- Aalok Agrawal - NED
- Hon Keong Choo - NED
- Elizabeth Desmond - NED
- Bradley Simpson - NED
- Zoe Tang - NED
- Rani Jadhav - IND
- H. C. H. Bhabha - NID
- C. R. Dua - NID
- Subramanian Madhavan - NID